Overview

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis

Status:
Not yet recruiting
Trial end date:
2027-10-29
Target enrollment:
Participant gender:
Summary
This is a single group, 1-arm, long-term safety study for treatment of participants with moderate to severe atopic dermatitis (AD). The purpose of this study is to characterize the long-term safety and efficacy of amlitelimab in treated adult participants with moderate to severe AD. The study duration per participant will be of 180 weeks, including: - A screening period of up to 2 to 4 weeks - An open label treatment period of at least 160 weeks (approximately 3 years) - A post-treatment safety follow-up period of up to 20 weeks after the last dose administration The planned number of visits will be 26 visits.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi